Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$11.84M-$11.84MN/M vs Q2 2025 EPS Diluted-$0.26-$0.26N/M vs Q2 2025 Operating Income-$13,377,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
ended Dec 31, 2025 · filed Feb 12, 2026 · 43 d after period end